J&J says booster shot provides 100 percent protection against severe COVID-19

New data indicates that a booster shot of Johnson & Johnson's vaccine provides 100 percent protection against severe COVID-19, the company announced Tuesday.
Johnson & Johnson said that in a phase 3 trial, a booster shot of its vaccine given after two months provided 94 percent protection against symptomatic COVID-19 in the United States, and it also provided 100 percent protection against severe COVID-19 "at least 14 days post-final vaccination." Antibody levels "rose to four to six times higher than observed after the single shot," the company said. The booster shot provided 75 percent protection globally.
"We now have generated evidence that a booster shot further increases protection against COVID-19 and is expected to extend the duration of protection significantly," Johnson & Johnson Chief Scientific Officer Paul Stoffels said.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Johnson & Johnson also said that when a booster was given six months after the first shot, there was a 12-fold increase in antibodies. The data suggests that "if you wait longer and have boost at six months or later then you likely will have better boost," Beth Israel Deaconess' Center for Virology and Vaccine Research head Dr. Dan Barouch explained to CNN.
Johnson & Johnson said it has provided this data to the Food and Drug Administration. An FDA advisory panel recently met to consider whether to authorize a booster shot of the Pfizer COVID-19 to those over 16 in the United States, but they ultimately decided not to do so, instead recommending it for those over 65 or at high risk for severe COVID-19. The Biden administration had initially planned to administer COVID-19 booster shots to all adults beginning this week. Administration health officials said last month that "booster shots will likely be needed for people who received the Johnson & Johnson" vaccine, and they said they would "keep the public informed with a timely plan" for administering these boosters once there was more data available.
Sign up for Today's Best Articles in your inbox
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Brendan worked as a culture writer at The Week from 2018 to 2023, covering the entertainment industry, including film reviews, television recaps, awards season, the box office, major movie franchises and Hollywood gossip. He has written about film and television for outlets including Bloody Disgusting, Showbiz Cheat Sheet, Heavy and The Celebrity Cafe.
-
Magazine solutions - February 28, 2025
Puzzles and Quizzes Issue - February 28, 2025
By The Week US Published
-
Magazine printables - February 28, 2025
Puzzles and Quizzes Issue - February 28, 2025
By The Week US Published
-
Lather up with these 8 eco-friendly shampoo bars
The Week Recommends Help your hair and the planet
By Catherine Garcia, The Week US Published
-
Ozempic can curb alcohol cravings, study finds
Speed read Weight loss drugs like Ozempic and Wegovy may also be helpful in limiting alcohol consumption
By Peter Weber, The Week US Published
-
New form of H5N1 bird flu found in US dairy cows
Speed Read This new form of bird flu is different from the version that spread through herds in the last year
By Peter Weber, The Week US Published
-
Microplastics accumulating in human brains, study finds
Speed Read The amount of tiny plastic particles found in human brains increased dramatically from 2016 to 2024
By Peter Weber, The Week US Published
-
FDA approves painkiller said to thwart addiction
Speed Read Suzetrigine, being sold as Journavx, is the first new pharmaceutical pain treatment approved by the FDA in 20 years
By Rafi Schwartz, The Week US Published
-
Study finds possible alternative abortion pill
Speed Read An emergency contraception (morning-after) pill called Ella could be an alternative to mifepristone for abortions
By Peter Weber, The Week US Published
-
How close are we to a norovirus vaccine?
Today's Big Question A new Moderna trial raises hopes of vanquishing a stomach bug that sickens millions a year
By David Faris Published
-
HMPV is spreading in China but there's no need to worry
The Explainer Respiratory illness is common in winter
By Devika Rao, The Week US Published
-
Marty Makary: the medical contrarian who will lead the FDA
In the Spotlight What Johns Hopkins surgeon and commentator Marty Makary will bring to the FDA
By David Faris Published